CanSino Biologics (HKG:6185, SHA:688185) said its new drug application for tetanus vaccine was accepted by the National Medical Products Administration of China, a Thursday bourse filing said.
Tetanus, a severe infectious disease, is caused by Clostridium tetani with a mortality rate reaching 30%-50% with medical intervention while the rate stands at 100% without medical intervention.
The vaccine, developed by the company, is aimed at non-neonatal tetanus prevention. It is safer as it is fermented with an animal-free culture medium, the filing said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。